BR112022023413A2 - Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume - Google Patents

Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume

Info

Publication number
BR112022023413A2
BR112022023413A2 BR112022023413A BR112022023413A BR112022023413A2 BR 112022023413 A2 BR112022023413 A2 BR 112022023413A2 BR 112022023413 A BR112022023413 A BR 112022023413A BR 112022023413 A BR112022023413 A BR 112022023413A BR 112022023413 A2 BR112022023413 A2 BR 112022023413A2
Authority
BR
Brazil
Prior art keywords
botulinum toxin
treatment
facial wrinkles
low volume
high dose
Prior art date
Application number
BR112022023413A
Other languages
English (en)
Portuguese (pt)
Inventor
Roll Susanna
Sladek Meik
Geister Thorin
Pulte Irena
Weissenberger Petra
Klein Gudrun
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71016459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022023413(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of BR112022023413A2 publication Critical patent/BR112022023413A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR112022023413A 2020-06-05 2021-06-04 Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume BR112022023413A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20178574 2020-06-05
PCT/EP2021/064986 WO2021245223A1 (en) 2020-06-05 2021-06-04 High dose and low volume botulinum toxin treatment of facial wrinkles

Publications (1)

Publication Number Publication Date
BR112022023413A2 true BR112022023413A2 (pt) 2022-12-20

Family

ID=71016459

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023413A BR112022023413A2 (pt) 2020-06-05 2021-06-04 Tratamento de rugas faciais com toxina botulínica de alta dose e baixo volume

Country Status (13)

Country Link
US (2) US12599550B2 (enExample)
EP (2) EP4161562B1 (enExample)
JP (2) JP2023529095A (enExample)
KR (1) KR20230020961A (enExample)
CN (1) CN115666629A (enExample)
AU (1) AU2021286196A1 (enExample)
BR (1) BR112022023413A2 (enExample)
CA (1) CA3177835A1 (enExample)
ES (1) ES3013130T3 (enExample)
IL (1) IL298399A (enExample)
MX (1) MX2022014564A (enExample)
TW (1) TW202214211A (enExample)
WO (1) WO2021245223A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume
TWI852454B (zh) * 2022-04-01 2024-08-11 大陸商重慶譽顏製藥有限公司 一種肉毒毒素蛋白組合物、製備方法及其應用
KR20250113431A (ko) * 2022-11-28 2025-07-25 메르츠 파마 게엠베하 운트 코. 카가아 목을 재생하기 위한 고 농도 보툴리눔 독소 치료
WO2025231403A1 (en) * 2024-05-03 2025-11-06 Revivity Pharma Corporation Methods of administering and manufacturing toxic compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
EP1786459B1 (en) 2004-07-26 2014-02-12 Merz Pharma GmbH & Co. KGaA Therapeutic composition whit a botulinum neurotoxin
EP2072039A1 (en) * 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
LT2761065T (lt) * 2011-09-29 2018-01-10 Cellsnap, Llc Kompozicijos ir būdai toksigeniškumo testavimui
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2020121540A (ru) 2017-12-04 2022-01-10 Реванс Терапьютикс, Инк. Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта
IL298399A (en) 2020-06-05 2023-01-01 Merz Pharma Gmbh & Co Kgaa Treatment of facial wrinkles with the botulinum toxin in high dose and low volume

Also Published As

Publication number Publication date
EP4161562A1 (en) 2023-04-12
EP4467202A2 (en) 2024-11-27
KR20230020961A (ko) 2023-02-13
US20260144733A1 (en) 2026-05-28
JP2023529095A (ja) 2023-07-07
MX2022014564A (es) 2022-12-15
EP4161562B1 (en) 2024-11-20
WO2021245223A1 (en) 2021-12-09
CN115666629A (zh) 2023-01-31
EP4467202A3 (en) 2025-02-19
TW202214211A (zh) 2022-04-16
CA3177835A1 (en) 2021-12-09
AU2021286196A1 (en) 2022-12-01
ES3013130T3 (en) 2025-04-11
JP2026077675A (ja) 2026-05-13
US12599550B2 (en) 2026-04-14
IL298399A (en) 2023-01-01
US20230329996A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
MX2022014564A (es) Tratamiento de arrugas faciales con toxina botulinica a dosis alta y volumen bajo.
Sethi et al. A review of complications due to the use of botulinum toxin A for cosmetic indications
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
AR061669A1 (es) Aplicacion de alta frecuencia de terapia con toxina botulinica
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
Naik Utilities of botulinum toxins in dermatology and cosmetology
RU2017120836A (ru) Контейнер, предварительно заполненный ботулиновым токсином
BRPI0514511A (pt) método para terapia percutánea hiperbárica com oxigênio por aspersão de fluorcarbonos
CN106215244A (zh) 透明质酸钠的复方溶液及其纠正皮肤皱纹的应用
JP2023529095A5 (enExample)
PL362923A1 (en) Compact architecture needleless syringe
BR112018009202A2 (pt) método para conectar dois objetos utilizando uma composição de polímero e um sistema para uso em um procedimento cosmético
US7858580B2 (en) Dermatological compositions including oligopeptides for increasing skin sensitivity and neuronal perception
Clark et al. Botulinum toxin: a treatment for facial asymmetry caused by facial nerve paralysis
MX2025006063A (es) Inyeccion de toxina botulinica en el platisma para el rejuvenecimiento de la parte inferior del rostro y el cuello
Lee et al. Recent clinical research on effect of acupuncture for autism spectrum disorder
Finzi Antidepressant effects of botulinum toxin A: scientific rationale
MX2023010718A (es) Composicion cosmetica prevista para el tratamiento de hiperpigmentacion de la piel y metodo de tratamiento que usa la composicion.
Raghuraman Comments on an article published in SLJA in July 2016
Inan Greater occipital nerve blockade for the treatment of chronic migraine
CHENG Symmetrical wrinkles eliminated unequilly after injection of botulinum A toxin
Liu et al. Differential effects of the calcitonin gene-related peptide on cardiac performance in acute myocardial ischemia and reperfusion in isolated rat hearts
Yun et al. Needleless Injection
Calderón-Pardo et al. New Molecules of Importance in the Prevention and Treatment of Acne: A Systematic Patent Review (2016-2020)
Vedamurthy Mesotherapy in Aesthetic Medicine